Skip to content
★ Sign in to follow
CR

Curtis Ruegg

Executive
Revance Therapeutics, Inc.
Total declarations
74
Company
1
▲ Purchases (0 ops.)
—
▼ Sales (39 ops.)
€700k

Latest filing published 15 Jun 2016 for Revance Therapeutics, Inc., €7,705.

Insider track record

Disclosed buys
0
Disclosed sells
39
Signal history

Curtis Ruegg: trading record in brief

Curtis Ruegg discloses dealings in Revance Therapeutics, Inc. to SEC (Form 4). We count 74 filings; the first trade dates from 19 May 2014 and the latest from 13 June 2016.

No open-market purchase appears, only 39 sales worth €700k. Besides market trades, the filings include 6 share grants and 29 option exercises. Since January 2016: no purchases and 6 sales on the market.

Most recently, on 15 June 2016, the filings show an option exercise worth €7,705 in Revance Therapeutics, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.

Companies and markets linked to Curtis Ruegg

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Declarations73 total

25 of 73 declarations